Carrier Global Corporation, global leader in intelligent climate and energy solutions, has officially announced the launch of Carrier Lynx FacTOR™, which happens to be a revolutionary software-as-a-service (SaaS) solution. geared towards rethinking the way product release processes are carried out across the pharmaceutical industry.
According to certain reports, Lynx FacTOR arrives on the scene bearing an ability to automate end-to-end product release evaluations, all for the purpose of minimizing manual processes and safely accelerating product movement in the cold chain.
Before we dig any further into the given solution, we must take into account how pharmaceuticals companies today have to put up with several different bottlenecks when it comes to ensuring product integrity throughout the distribution journey. These challenges include manual processes, costly delays, siloed data, and strict compliance requirements that all come together to often hinder timely product releases at their next or final destination.
Contextualizing the need of a breakthrough even more is how current processes being used in the current context have shown to involve extremely long evaluation of excursion events, taking multiple days to complete assessments and weeks or months for root cause analysis and correction.
Furthermore, with multiple sources of data to collect and analyze, determining product and batch integrity after shipment temperature breaches becomes a complex and labor-intensive task, a task which can potentially cost companies millions of dollars annually in manual labor inefficiencies.
Against that problem statement, Lynx FacTOR brings to the fore a single source of truth for the entire pharmaceutical distribution lifecycle. Such a device-agnostic solution, you see, can automatically evaluate product viability at the batch level so to reduce assessment times from days to minutes.
All in all, by simplifying processes and providing recommendations, Lynx FacTOR can tread up a long distance to scale up the quality of decision-making and compliance across regions.
“Lynx FacTOR represents a major leap forward in pharmaceutical supply chain management,” said Alice DeBiasio, Vice President & General Manager of Truck Trailer Americas and Digital Solutions at Carrier. “As cold chain experts, Carrier understands the unique requirements and challenges of the pharmaceutical industry. By automating the assessment process, we are not only speeding up product releases but also enhancing accuracy and compliance, ultimately enhancing patient safety.”
Talk about the whole value proposition on a slightly deeper, we begin from its ability to automate, something which makes it possible for the underlying technology to streamline the product stability assessment process with automated calculations and rule-based protocols that, on their part, reduce human error and improve standardization.
This then goes on to enhance regulatory compliance, while simultaneously improving accuracy at all touchpoints in a supply chain.
Next up, we must dig into the solution’s evaluation capabilities. Here, the idea is to acquire real-time insights with a comprehensive analysis, which consolidates pharmaceutical companies’ data from multiple sources. Users can also come expecting to assess product viability and stability status in minutes, thus enabling the pharmaceutical companies to make informed decisions and minimize risks.
Another detail worth a mention here is rooted in the potential for acceleration. Basically, Lynx FacTOR can greatly speed up product release decisions at every step of the distribution funnel. The intention behind doing so is to increase quality process productivity, reduce order lead times, and enhance overall efficiency.
“Lynx FacTOR is a game-changer for the life sciences and pharma industry,” said Bhasker Kaushal, Vice President & General Manager at Sensitech & Aftermarket and Vice President of Strategy and Business Development at Carrier. “By enabling end-to-end supply chain visibility, digitizing workflows and automating complex analyses, we are reducing the time and effort required to ensure product quality and compliance. This not only accelerates the distribution of critical medicines but also enhances overall operational efficiency.”
